Skip to main content

Advertisement

Table 2 Regression analyses comparing biomarkers between all disease groups classified according to pre-lumbar puncture diagnosis, with and without healthy controls

From: Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

  Global test* including HC (p value) Global test** excluding HC (p value) Adjusted*** global test excluding HC (p value)
Aβ1–42 < 0.0001 < 0.0001 < 0.0001
T-tau < 0.0001 < 0.0001 < 0.0001
T-tau/Aβ1–42 ratio < 0.0001 < 0.0001 < 0.0001
P-tau-181 < 0.0001 < 0.0001 < 0.0001
NFL < 0.0001 < 0.0001 < 0.0001
YKL-40 0.0038 0.51 0.04
AβX-38 < 0.0001 0.43 0.17
AβX-40 < 0.0001 0.57 0.30
AβX-42 < 0.0001 0.0001 0.0002
AβX-42/X-40 ratio < 0.0001 < 0.0001 < 0.0001
APPα < 0.0001 < 0.0001 0.0001
APPβ < 0.0001 0.0001 0.0001
  1. Biomarker data are log transformed to achieve normal distribution
  2. amyloid beta, APP amyloid precursor protein, HC healthy controls, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau
  3. *p < 0.05 provides evidence that the disease groups, including the HC group, do not all have the same mean biomarker value
  4. **As for *, excluding control group
  5. ***As for **, also adjusting for age, sex, and time from symptom onset to lumbar puncture